Protection from enteric pathogens by beneficial microbes
通过有益微生物预防肠道病原体
基本信息
- 批准号:8546976
- 负责人:
- 金额:$ 14.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-18 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnti-Inflammatory AgentsAnti-inflammatoryAttenuatedBacillus (bacterium)Bacillus licheniformisBacillus subtilisBacteriaC-Type LectinsCD4 Positive T LymphocytesCellsChildCitrobacter rodentiumDiseaseDoseEscherichia coli EHECExposure toFlagellinFlow CytometryGastrointestinal tract structureGoalsGrantHomeostasisImmuneImmune responseInflammationInflammatory ResponseInflammatory disease of the intestineIntestinesKnock-outKnockout MiceLigandsLuciferasesMediatingMesenteryMicrobeMusNatural ImmunityOralPeptidoglycanRIPK2 geneReceptor SignalingRegulatory T-LymphocyteReproduction sporesSiteTLR2 geneTLR5 geneTestingToll-like receptorsbioluminescence imagingcommensal microbesdesignenteric pathogenin vivointestinal epitheliumkillingslymph nodesmutantpathogenpreventreceptorresearch study
项目摘要
DESCRIPTION (provided by applicant): The host and its commensal microbiota generally maintain a peaceful coexistence; however, a few bacteria disrupt immune homeostasis and cause disease. For example, attaching and effacing (A/E) enteropathogenic and enterohemorrhagic E. coli (EPEC and EHEC) cause diarrheal diseases that affect more than 2 billion people and kill 1.5 million children annually. Commensal bacteria can protect the host from disease caused by enteric pathogens; however, the mechanisms by which this occurs are poorly understood. We recently found that a single oral dose of commensal Bacillus subtilis or Bacillus formis spores can protect mice from disease caused by the A/E pathogen, Citrobacter rodentium. In contrast, a closely related commensal Bacillus licheniformis, and two B. subtilis mutants, hag and espH, did not protect the host. Because the single dose of protective Bacillus spp. is given 24 hr prior to pathogenic C. rodentium, protection is not likely due to initiation of an adaptive immune response, but is more likely due to an innate anti-inflammatory immune response. Alternatively, Bacillus spp. could protect from disease by directly interfering with localization of C. rodentium to the intestinal epithelium. In Aim 1 we will use in vivo bioluminescence imaging (IBIS) to determine if protective Bacillus spp. alter the colonization site of pathogenic C. rodentium. One of the non-protective B. subtilis mutants is deficient in flagellin, a ligand for TLR5, and another is deficient in exopolysaccharide, presumed ligand for TLR2, and in Aim 2 we will use TLR agonists and TLR knockout mice to determine if protection is mediated through TLR. Similarly, we will use Nod-like receptor (NLR) agonists and knockout mice to determine if protection is mediated through NLR. In Aim 3, we will test the possibility that B. subtilis mediates protection through T regulatory cells.
描述(由申请人提供):宿主及其肠道微生物群通常保持和平共处;然而,少数细菌破坏免疫稳态并引起疾病。例如,附着和消除(A/E)肠致病性和肠出血性E。大肠杆菌(EPEC和EHEC)引起的肠道疾病每年影响超过20亿人,并导致150万儿童死亡。共生细菌可以保护宿主免受肠道病原体引起的疾病的侵害;然而,这种情况发生的机制知之甚少。我们最近发现,单次口服剂量的枯草芽孢杆菌或芽孢杆菌孢子可以保护小鼠免受由A/E病原体啮齿柠檬酸杆菌引起的疾病。与此相反,一个密切相关的地衣芽孢杆菌,和两个B。枯草杆菌突变体hag和espH不能保护宿主。因为单剂量的保护性芽孢杆菌。在致病性C之前24小时给予。在啮齿动物中,保护不太可能是由于适应性免疫应答的启动,而更可能是由于先天性抗炎免疫应答。或者,芽孢杆菌属(Bacillus spp.)可以通过直接干扰C.啮齿动物的肠上皮细胞。在目标1中,我们将使用体内生物发光成像(IBIS)来确定是否保护芽孢杆菌属。改变致病性C.啮齿动物。其中一个非保护性的B。枯草芽孢杆菌突变体缺乏鞭毛蛋白(TLR 5的配体),另一种缺乏胞外多糖(推测为TLR 2的配体),在目的2中,我们将使用TLR激动剂和TLR敲除小鼠来确定保护是否通过TLR介导。同样,我们将使用Nod样受体(NLR)激动剂和基因敲除小鼠来确定保护是否是通过NLR介导的。在目标3中,我们将测试B.枯草芽孢杆菌通过调节性T细胞介导保护作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katherine L. Knight其他文献
Genetic control of alpha chains of rabbit IgA: allotypic specificities on the variable and the constant regions.
兔 IgA α 链的遗传控制:可变区和恒定区的同种异型特异性。
- DOI:
- 发表时间:
1975 - 期刊:
- 影响因子:0
- 作者:
Katherine L. Knight;W. Hanly - 通讯作者:
W. Hanly
Exopolysaccharide-treated Dendritic Cells Effectively Ameliorate Acute Graft vs Host Disease.
胞外多糖处理的树突状细胞可有效改善急性移植物抗宿主病。
- DOI:
10.1016/j.jtct.2023.10.023 - 发表时间:
2023 - 期刊:
- 影响因子:3.2
- 作者:
O. Kalinina;L. Minter;Anne I. Sperling;M. K. Hollinger;Phong Le;Barbara A. Osborne;Shubin Zhang;Patrick Stiff;Katherine L. Knight - 通讯作者:
Katherine L. Knight
Identification and genetic control of two rabbit high-density lipoprotein allotypes
- DOI:
10.1007/bf00486087 - 发表时间:
1972-10-01 - 期刊:
- 影响因子:1.600
- 作者:
Alice Gilman-Sachs;Katherine L. Knight - 通讯作者:
Katherine L. Knight
Intestinal bacteria and development of the B-lymphocyte repertoire
- DOI:
10.1016/j.it.2005.06.001 - 发表时间:
2005-08-01 - 期刊:
- 影响因子:
- 作者:
Dennis K. Lanning;Ki-Jong Rhee;Katherine L. Knight - 通讯作者:
Katherine L. Knight
Contribution of the allelicMtz 3 andMtz 4 allotype genes to the formation of individual rabbit serum α2-macroglobulin molecules
- DOI:
10.1007/bf00486080 - 发表时间:
1972-10-01 - 期刊:
- 影响因子:1.600
- 作者:
Bernard H. Berne;Sheldon Dray;Katherine L. Knight - 通讯作者:
Katherine L. Knight
Katherine L. Knight的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katherine L. Knight', 18)}}的其他基金
Development of a mucosal vaccine to prevent Clostridium difficile infection using papilloma pseudovirus as a vector.
使用乳头状瘤假病毒作为载体开发粘膜疫苗以预防艰难梭菌感染。
- 批准号:
10213890 - 财政年份:2020
- 资助金额:
$ 14.19万 - 项目类别:
Prevention of GVHD by a probiotic exopolysaccharide.
通过益生菌胞外多糖预防 GVHD。
- 批准号:
10081555 - 财政年份:2020
- 资助金额:
$ 14.19万 - 项目类别:
Commensal Exopolysaccharide Protection from Inflammation
共生胞外多糖预防炎症
- 批准号:
8888736 - 财政年份:2015
- 资助金额:
$ 14.19万 - 项目类别:
Protection from enteric pathogens by beneficial microbes
通过有益微生物预防肠道病原体
- 批准号:
8256331 - 财政年份:2012
- 资助金额:
$ 14.19万 - 项目类别:
Somatic Diversification of Immunoglobulin Genes in Galt
Galt 免疫球蛋白基因的体细胞多样化
- 批准号:
8321129 - 财政年份:2011
- 资助金额:
$ 14.19万 - 项目类别:
Maintaining B cell immunity with aged B lymphocytes
用老化的 B 淋巴细胞维持 B 细胞免疫
- 批准号:
7878421 - 财政年份:2009
- 资助金额:
$ 14.19万 - 项目类别:
Maintaining B cell immunity with aged B lymphocytes
用老化的 B 淋巴细胞维持 B 细胞免疫
- 批准号:
8015990 - 财政年份:2007
- 资助金额:
$ 14.19万 - 项目类别:
Maintaining B cell immunity with aged B lymphocytes
用老化的 B 淋巴细胞维持 B 细胞免疫
- 批准号:
7365169 - 财政年份:2007
- 资助金额:
$ 14.19万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 14.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 14.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)